



Financial Statements

As of and For the Years Ended December 31, 2024 and 2023

with Independent Auditor's Report

ALASKA VACCINE ASSESSMENT PROGRAM
Table of Contents
As of and For the Year Ended December 31, 2024

Independent Auditor's Report.....	1-3
Financial Statements	
Statements of Net Assets-Regulatory basis	4
Statements of Activities-Regulatory basis	5-6
Statements of Cash Flows-Regulatory basis	7
Notes to the Financial Statements	8-10
Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	11-12



INDEPENDENT AUDITOR'S REPORT

To the Council Members
Alaska Vaccine Assessment Program
Anchorage, Alaska

Report on Audit of the Financial Statements

Opinion

I have audited the accompanying financial statements of the Alaska Vaccine Assessment Program, which comprise the statements of net assets-regulatory basis as of December 31, 2024 and 2023, and the related statements of activities-regulatory basis and cash flows-regulatory basis for the years then ended, and the related notes to the financial statements.

In my opinion, the financial statements referred to above present fairly, in all material respects, the net assets of the Alaska Vaccine Assessment Program as of December 31, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended, in accordance with the financial reporting provisions of the Alaska Vaccine Assessment Program as described in Note 2.

Basis for Opinion

I conducted my audit in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. My responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of my report. I am required to be independent of the Alaska Vaccine Assessment Program and to meet my other ethical responsibilities, in accordance with relevant ethical requirements relating to my audit. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my audit opinion.

Emphasis of Matter – Basis of Accounting

I draw attention to Note 2 of the financial statements, which describes the basis of accounting. The financial statements are prepared on the basis of the financial reporting provisions, defined by the Council of the Alaska Vaccine Assessment Program, which is a basis of accounting other than accounting principles generally accepted in the United States of America, to comply with the requirements of the Alaska Vaccine Assessment Program. As a result, the financial statements may not be suitable for another purpose. My opinion is not modified with respect to that matter.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with the financial reporting provisions of the Alaska Vaccine Assessment Program, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Alaska Vaccine Assessment Program's ability to continue as a going concern for one year after the date the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

My objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, I

- exercise professional judgment and maintain professional skepticism throughout the audit.
- identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Alaska Vaccine Assessment Program's internal control. Accordingly, no such opinion is expressed.
- evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- conclude whether, in my judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Alaska Vaccine Assessment Program's ability to continue as a going concern for a reasonable period of time.

I am required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that I identified during the audit.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, I have also issued a report dated May 2, 2025, on my consideration of Alaska Vaccine Assessment Program's internal control over financial reporting and on my tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, and other matters. The purpose of that report is solely to describe the scope of my testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Alaska Vaccine Assessment Program's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Alaska Vaccine Assessment Program's internal control over financial reporting and compliance.

Restrictions on Use

Because the financial statements are prepared on the basis of the financial reporting provisions, as defined by the Council of the Alaska Vaccine Assessment Program, which is a basis of accounting other than accounting principles generally accepted in the United States of America, this report is intended solely for the information and use of the Council Members, State of Alaska, and management of the Alaska Vaccine Assessment Program and is not intended to be and should not be used by anyone other than those specified parties.

May 2, 2025



Blaine, Washington

ALASKA VACCINE ASSESSMENT PROGRAM
Statements of Net Assets - Regulatory Basis
December 31, 2024 and 2023

	<u>2024</u>	<u>2023</u>
ASSETS		
Cash		
Held by the State of Alaska	\$ 31,652,966	\$ 19,545,759
Held by KidsVax® LLC	<u>25,251</u>	<u>5,036</u>
	<u>31,678,217</u>	<u>19,550,795</u>
Assessments receivable		
Payers - TRICARE	991,794	484,230
Payers	94,994	39,794
Providers	<u>246,884</u>	<u>-</u>
Total assessments receivable	1,333,672	524,024
Allowance for uncollectible assessments	<u>(991,794)</u>	<u>(484,230)</u>
Net assessments receivable	<u>341,878</u>	<u>39,794</u>
 Total assets	 <u><u>\$ 32,020,095</u></u>	 <u><u>\$ 19,590,589</u></u>
LIABILITIES		
Accounts payable		
Vaccines	816,374	3,657,839
KidsVax®	36,042	25,427
Refunds due to payers/providers	<u>1,089</u>	<u>873</u>
	853,505	3,684,139
Assessments collected in excess of vaccine funding and administrative activities	<u>19,969,668</u>	<u>6,593,423</u>
 Total liabilities	 <u>20,823,173</u>	 <u>10,277,562</u>
NET ASSETS		
Restricted funds due to Department of Health	<u>11,196,922</u>	<u>9,313,027</u>
 Total liabilities and net assets	 <u><u>\$ 32,020,095</u></u>	 <u><u>\$ 19,590,589</u></u>

The accompanying notes should be read with these financial statements.

ALASKA VACCINE ASSESSMENT PROGRAM
Statement of Activities - Regulatory Basis
For the Year Ended December 31, 2024

	Assessments Collected in Excess of Vaccine Funding and Administrative Activities	Restricted funds Due to DHSS	2024 Total
Assessments			
Payer assessments - children	\$ 15,603,063	\$ -	\$ 15,603,063
Payer assessments - adults	10,986,576	-	10,986,576
Provider assessments	1,258,402	-	1,258,402
Total revenue	27,848,041	-	27,848,041
Change in allowance for doubtful collections	(507,564)	-	(507,564)
Net operating revenue	27,340,477	-	27,340,477
Investment income - payers	9,827	-	9,827
Investment income - State of AK	746,106	632,593	1,378,699
Net revenue	28,096,410	632,593	28,729,003
Program expense			
Vaccines	12,903,226	-	12,903,226
Servicing agent	400,655	-	400,655
	13,303,881	-	13,303,881
Administrative costs	23,882	-	23,882
DHSS administrative fee	1,392,402	(1,392,402)	-
Authorized DHHS expenditures	-	141,100	141,100
Total expenses	14,720,165	(1,251,302)	13,468,863
Net activity	13,376,245	1,883,895	15,260,140
Balance, beginning of year	6,593,423	9,313,027	15,906,450
Balance, end of year	\$ 19,969,668	\$ 11,196,922	\$ 31,166,590

The accompanying notes should be read with these financial statements.

ALASKA VACCINE ASSESSMENT PROGRAM
Statement of Activities - Regulatory Basis
For the Year Ended December 31, 2023

	Assessments Collected in Excess of Vaccine Funding and Administrative Activities	Restricted funds Due to DHSS	2023 Total
Assessments			
Payer assessments - children	\$ 10,126,493	\$ -	\$ 10,126,493
Payer assessments - adults	4,549,217	-	4,549,217
Provider assessments	<u>557,371</u>	<u>-</u>	<u>557,371</u>
Total revenue	15,233,081	-	15,233,081
Change in allowance for doubtful collections	<u>(74,437)</u>	<u>-</u>	<u>(74,437)</u>
Net operating revenue	15,158,644	-	15,158,644
Investment income - payers	1,097		1,097
Investment income - State of AK	<u>463,525</u>	<u>546,987</u>	<u>1,010,512</u>
Net revenue	<u>15,623,266</u>	<u>546,987</u>	<u>16,170,253</u>
Program expense			
Vaccines	14,678,451	-	14,678,451
Servicing agent	<u>405,119</u>	<u>-</u>	<u>405,119</u>
	15,083,570	-	15,083,570
Administrative costs	24,526	-	24,526
DHSS administrative fee	761,652	(761,652)	-
Authorized DHHS expenditures	<u>-</u>	<u>139,540</u>	<u>139,540</u>
Total expenses	<u>15,869,748</u>	<u>(622,112)</u>	<u>15,247,636</u>
Net activity	(246,482)	1,169,099	922,617
Balance, beginning of year	<u>6,839,905</u>	<u>8,143,928</u>	<u>14,983,833</u>
Balance, end of year	<u><u>\$ 6,593,423</u></u>	<u><u>\$ 9,313,027</u></u>	<u><u>\$ 15,906,450</u></u>

The accompanying notes should be read with these financial statements.

ALASKA VACCINE ASSESSMENT PROGRAM
Statements of Cash Flows - Regulatory Basis
For the Years Ended December 31, 2024 and 2023

	<u>2024</u>	<u>2023</u>
Cash receipts of assessments	\$ 27,038,609	\$ 15,194,568
Cash receipts of interest	9,827	1,097
Cash disbursements for vaccines	(15,744,691)	(12,929,714)
Cash disbursements for other costs	(413,922)	(429,645)
Cash disbursements of restricted funds	(141,100)	(139,540)
Increase (Decrease) in cash balance due to investment income (loss)	<u>1,378,699</u>	<u>1,010,512</u>
 Cash flows from operating activities	 <u><u>\$ 12,127,422</u></u>	 <u><u>\$ 2,707,278</u></u>
 Cash Flows from Operating Activities:		
Change in net assessments collected	\$ 13,376,245	\$ (246,482)
Net activity in restricted funds	1,883,895	1,169,099
Adjustments to reconcile change in net assessments collected to net cash from operating activities:		
Changes in assets and liabilities		
Assessments receivable	(809,648)	(28,977)
Allowance for uncollectible assessments	507,564	65,985
Accounts payable - vaccines	(2,841,465)	1,748,737
Accounts payable - nonvaccine purchases	10,615	-
Refunds due	<u>216</u>	<u>(1,084)</u>
Cash flows from operating activities	<u><u>12,127,422</u></u>	<u><u>2,707,278</u></u>
 Net change in cash	 12,127,422	 2,707,278
 Cash, beginning of year	 <u>19,550,795</u>	 <u>16,843,517</u>
 Cash, ending of year	 <u><u>\$ 31,678,217</u></u>	 <u><u>\$ 19,550,795</u></u>

The accompanying notes should be read with these financial statements.

ALASKA VACCINE ASSESSMENT PROGRAM
Notes to the Financial Statements
For the Years Ended December 31, 2024 and 2023

NOTE 1 – NATURE AND PURPOSE OF THE PROGRAM

The Alaska Vaccine Assessment Program (AVAP) (the Program) is a program enacted by the State of Alaska legislature in June 2014 and authorized under Alaska Statute 18.09.200 to establish a vaccine assessment account that will enable the Alaska Department of Health (DOH) to purchase all pediatric and most adult vaccines at costs below those of private purchase alternatives.

AVAP facilitates the universal purchase of vaccines in Alaska. It provides funding for all vaccines federally recommended for insured children and for certain adult vaccines selected by the DOH. By collecting payments from health plans, insurers, and other responsible entities and remitting those funds to the State of Alaska, AVAP ensures

- Alaskans gain improved access to vaccines;
- Health care providers receive state-supplied vaccines at no charge; and
- Payers benefit from cost savings through the State's bulk vaccine purchase and distribution.

DOH contracted with KidsVax, LLC based in New Hampshire as the servicing agent for administrative support services, including collection of payments from health plans, insurance companies, and other payers and providers.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying financial statements are prepared from the activities provided for under the Alaska Vaccine Assessment Program, and represent a basis of accounting other than accounting principles generally accepted in the United States of America. The financial statements include the assessments billed to participating payers and providers, as determined by the provisions of the Program, and the expenses that are allowed to be paid from the Program, including vaccines and the costs for administering the program. Vaccines are considered to be an expense of the Program when ordered and an inventory balance is not recognized.

Cash and cash equivalents

Cash represents funds held by the State of Alaska and KidsVax for the benefit of the Alaska Vaccine Assessment Program.

Assessments receivable

Assessments receivable are stated at the amounts management expects to collect from outstanding balances. Management provides for doubtful receivables through an allowance based on its consideration of the current status of individual receivables.

ALASKA VACCINE ASSESSMENT PROGRAM
Notes to the Financial Statements
For the Years Ended December 31, 2024 and 2023

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, continued

Assessments collected in excess of vaccine funding and administrative activities

AVAP has collected assessments in excess of amounts required to fund Childhood and Adult vaccines and associated administrative costs. Net assessments collected accumulate and will be used for timely funding of (i) future vaccine funding obligations of the program and (ii) reasonable and necessary operating costs of AVAP.

Restricted funds due to Department of Health

Alaska Vaccine Assessment Program owes DOH for vaccines paid for at the inception of the program, assessments collected on behalf of DOH, and for the annual administrative fee payable to DOH. Alaska Vaccine Assessment Program has paid costs as authorized by DOH, on their behalf, and these amounts have been deducted from amounts owed to DOH. All funds due to DOH are not available to AVAP.

Revenue recognition

Assessments are recognized when billed to participating payers and providers based on the number of covered lives. Assessments are billed to payers on a quarterly basis and to providers on an annual basis. Assessment rates per covered life are recommended by the State Vaccine Assessment Council and approved by the Commissioner of the State of Alaska Department of Health on an annual basis.

Investment income earned (or losses incurred) on funds pooled with the State of Alaska funds has been allocated between restricted funds due to DOH and AVAP based on pro-rata balances on a monthly basis.

Expenses

The terms of the Program allow for DOH to charge an administrative fee of five percent (5.0%) of total revenue less credits approved by the Council, for the years ended December 31, 2024 and 2023, respectively. This fee is for direct and indirect costs incurred by DOH in its administration of the Program.

The servicing agent earns its fee on a monthly basis in accordance with services provided to the Program. Amounts outstanding to KidsVax, LLC at December 31, 2024 and 2023 totaled \$36,042 and \$25,427, respectively.

Use of estimates in preparation of financial statements

The preparation of financial statements in conformity with the regulatory basis of accounting requires management to make estimates and assumptions that affect reported amounts and disclosure of assets and liabilities. Actual results could differ from those estimates.

ALASKA VACCINE ASSESSMENT PROGRAM
Notes to the Financial Statements
For the Years Ended December 31, 2024 and 2023

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, continued

Subsequent events

Subsequent events have been evaluated through May 2, 2025, which approximates the date the financial statements were available to be issued.

NOTE 3 – CONCENTRATIONS OF RISK

For the year ended December 31, 2024, two payers represented 48% the assessment revenue. For the year ended December 31, 2023, two payers represented 47% the assessment revenue.

For the year ended December 31, 2024, one payer represented 74% the accounts receivable. For the year ended December 31, 2023, one payer represented 89% the accounts receivable.

NOTE 4 – COLLECTION OF ASSESSMENTS IN ARREARS

Through its administrator, KidsVax, LLC (KV), AVAP has been pursuing collection from the federal Defense Health Agency (DHA) assessments for TRICARE beneficiaries residing in the State of Alaska. AVAP has benefitted from KV's multistate efforts to secure supportive federal legislation. Effective December 23, 2016, Congress adopted Section 719 of the 2017 National Defense Authorization Act (NDAA) which authorized the DHA to make payments to AVAP and certain other state vaccine programs. The 2017 NDAA provides for reimbursement of the amount assessed by AVAP generally but with certain limits. Section 718 of the 2018 NDAA made such DHA payments mandatory.

Commencing in May of 2018, TRICARE started making regular AVAP assessment payments. AVAP and KV disagree with TRICARE's ongoing assessment reduction methodologies and reserve all legal rights to pursue recovery of these sums. In accordance with accounting principles, an allowance has been recorded for the receivable due by TRICARE and its affiliated entities in its entirety,



INDEPENDENT AUDITOR'S REPORT
ON INTERNAL CONTROL OVER FINANCIAL REPORTING
AND ON COMPLIANCE AND OTHER MATTERS
BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED
IN ACCORDANCE WITH *GOVERNMENT AUDITING STANDARDS*

To the Council Members
Alaska Vaccine Assessment Program
Anchorage, Alaska

I have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the financial statements of Alaska Vaccine Assessment Program which comprise the statement of net assets-regulatory basis as of December 31, 2024 and 2023, and the related statements of activities-regulatory basis and cash flows-regulatory basis for the years then ended, and the related notes to the financial statements, and have issued my report thereon dated May 2, 2025.

Report on Internal Control over Financial Reporting

In planning and performing my audit of the financial statements, I considered Alaska Vaccine Assessment Program's internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing my opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Alaska Vaccine Assessment Program's internal control over financial reporting. Accordingly, I do not express an opinion on the effectiveness of Alaska Vaccine Assessment Program's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

My consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during my audit I did not identify any deficiencies in internal control that I consider to be a material weakness. However, material weaknesses or significant deficiencies may exist that have not been identified.

Independent Auditor's Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

Page 2

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether Alaska Vaccine Assessment Program's financial statements are free of material misstatement, I performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of my audit, and accordingly, I do not express such an opinion. The results of my tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of my testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

May 2, 2025

A handwritten signature in blue ink that reads "Laura Lindal CPA". The signature is written in a cursive, flowing style.

Blaine, Washington